FDA Approves Topical Foam for Plaque Psoriasis of the Scalp and Body

Zoryve roflumilast

TUESDAY, May 27, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Zoryve (roflumilast) topical foam 0.3 percent for the treatment of plaque psoriasis of the scalp and body in adult and pediatric patients 12 years of age and older.

Through a supplemental new drug application, Zoryve foam was approved as a once-daily, steroid-free topical treatment.

Originally published on healthday.com, part of the BLOX Digital Content Exchange.